`Date Filed: August 8, 2018
`
`
`Filed On Behalf Of:
`Novartis Pharmaceuticals Corporation
`
`By:
`Nicholas N. Kallas
`NKallas@fchs.com
`ZortressAfinitorIPR@fchs.com
`(212) 218-2100
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED.
`
`Petitioner,
`
`v.
`
`NOVARTIS PHARMACEUTICALS CORPORATION,
`
`Patent Owner.
`
`
`
`Case IPR2017-015921
`
`Patent No. 8,410,131
`
`
`
`PATENT OWNER’S EXHIBIT LIST 9
`
`
`
`
`
`
`
`1 IPR2018-00507 has been joined to this proceeding (Paper 29, Apr. 03, 2018).
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`Expert Declaration Of Howard A. Burris, III,
`M.D.
`
`Burris Decl.
`
`Curriculum Vitae Of Howard A. Burris, III,
`M.D.
`
`Burris C.V.
`
`2001
`
`2002
`
`2003
`
`Laughlin, E.H., Coming To Terms With
`Cancer: A Glossary Of Cancer-Related Terms,
`pages 4, 126, 140, 173-174, 188-190 (2002)
`
`2004
`
`Altman, R. & Sarg, M.J., The Cancer
`Dictionary, 51-52, 278 (1992)
`
`2005
`
`2006
`
`2007
`
`Sutcliffe, S.B. & Gospodarowicz, M.K.,
`Chapter 25, “Primary Extranodal
`Lymphomas,” The Lymphomas (Canellos, G.P.
`et al. eds., 1998)
`
`Molina, A. & Pezner, R.D., Chapter 30, “Non-
`Hodgkin’s Lymphoma,” Cancer Management:
`A Multidisciplinary Approach: Medical,
`Surgical, & Radiation Oncology, 4th Edition
`(Pazdur, R. et al. eds., 2000)
`
`Sutcliffe, S.B. & Gospodarowicz, M.K.,
`“Clinical Features And Management Of
`Localized Extranodal Lymphomas,”
`Haematological Oncology, Volume 2 pages
`189-222 (Keating, A. et al. eds., 1992)
`
`Laughlin
`
`Altman
`
`Sutcliffe 1998
`
`Pazdur
`
`Sutcliffe
`
`2008
`
`Lynch, C.F. & Cohen, M.B., “Urinary
`System,” Cancer 75(1 Suppl.): 316-329 (1995)
`
`Lynch
`
`2009
`
`Ligato, S. et al., “Benign Tumors And Tumor-
`Like Lesions Of The Adult Kidney Part I:
`Benign Renal Epithelial Neoplasms,” Adv.
`Anat. Pathol. 6(1): 1-11 (1999)
`
`Ligato
`
`
`
`1
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`Glenn, G.M. et al., Chapter 75, “The Molecular
`Genetics Of Renal Cell Carcinoma,” Principles
`And Practice Of Genitourinary Oncology
`(Raghavan, D. et al. eds., 1997)
`
`Glenn
`
`Hyland, S. & Wilkinson, D., Chapter 14, “The
`Nurse Practitioner And The Organization Of
`Support Services For The Patient With
`Genitourinary Cancer,” Principles And
`Practice Of Genitourinary Oncology
`(Raghavan, D. et al. eds., 1997)
`
`Vasey, P.A., “Immunotherapy For Renal
`Carcinoma: Theoretical Basis And Current
`Standard Of Care,” Br. J. Clin. Pharmacol. 50:
`521-529 (2000)
`
`Kawai, K. et al., “Ex Vivo Gene Therapy
`Using Granulocyte-Macrophage Colony-
`Stimulating Factor-Transduced Tumor
`Vaccines,” Mol. Urol. 4(2): 43-46 (2000)
`
`Adjei, A.A., “Signal Transduction Pathway
`Targets For Anticancer Drug Discovery,” Cur.
`Pharm. Design 6: 361-378 (2000)
`
`Gordon, M.S. et al., “Phase I Safety And
`Pharmacokinetic Study Of Recombinant
`Human Anti-Vascular Endothelial Growth
`Factor In Patients With Advanced Cancer,” J.
`Clin. Oncol. 19(3): 843-850 (2001)
`
`Penn, I. & Starzl, T.E., “Immunosuppression
`And Cancer,” Transplant Proc. 5(1): 943-947
`(1973)
`
`January 19, 2016 Office Action, Prosecution
`File History Of U.S. Patent Application No.
`13/893,537
`
`Hyland
`
`Vasey
`
`Kawai
`
`Adjei
`
`Gordon
`
`Penn
`
`
`
`
`
`2
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2018
`
`January 27, 2016 Office Action, Prosecution
`File History Of U.S. Patent Application No.
`13/893,589
`
`October 17, 2006 Official Communication and
`February 26, 2007 Applicant Response
`(received February 27, 2007), Prosecution File
`History Of European Patent Application No. 01
`903 095.6-2112 (International Application No.
`PCT/US01/01537)
`
`Declaration In Support Of Patent Owner
`Novartis’s Motion For Pro Hac Vice
`Admission Of Christina Schwarz Under 37
`C.F.R. § 42.10
`
`Declaration In Support Of Patent Owner
`Novartis’s Motion For Pro Hac Vice
`Admission Of Charlotte Jacobsen Under 37
`C.F.R. § 42.10
`
`Declaration In Support Of Patent Owner
`Novartis’s Motion For Pro Hac Vice
`Admission Of Susanne L. Flanders Under 37
`C.F.R. § 42.10
`
`
`
`
`
`
`
`
`
`
`
`2019
`
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`Kozlowski, J.M. et al., Chapter 78, “Renal Cell
`Carcinoma, Tumor Markers,” Principles And
`Practice Of Genitourinary Oncology
`(Raghavan, D. et al. eds., 1997)
`
`Kozlowski
`
`Motzer, R.J. & Russo, P., “Systemic Therapy
`For Renal Cell Carcinoma,” J. Urology
`163:408-417 (2000)
`
`Russo
`
`Physicians’ Desk Reference, 55th Edition
`(2001), pages 3443-3448 (Entry for
`Rapamune® Oral Solution (Sirolimus))
`
`Rapamune®
`PDR
`
`
`
`3
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2026
`
`2027
`
`2028
`
`Document Stamped At The March 13, 2018
`Deposition Of Dr. Allan J. Pantuck
`
`
`
`March 13, 2018 Deposition Testimony of Dr.
`Allan J. Pantuck
`
`Pantuck
`
`Truong, L. et al., “The Diagnostic and
`Therapeutic Roles of Fine-Needle Aspiration,”
`Am. J. Clin. Pathol. 115:18-31 (2001)
`
`Truong
`
`2029
`
`Hanahan, D. & R.A. Weinberg, “The
`Hallmarks of Cancer,” Cell 100:57-70 (2000)
`
`Hanahan
`
`2030
`
`Abbas, Z. et al., “Renal lymphoma: an unusual
`cause of extrahepatic biliary obstruction,”
`Postgraduate Med. J. 617-18 (1996)
`
`Abbas
`
`2031
`
`“Genitourinary,” Stedman’s Medical
`Dictionary 738-39 (27th ed. 2000)
`
`Stedman’s
`
`2032
`
`Braybrooke, J.P. et al., “A Phase II Study of
`Razoxane, an Antiangiogenic Topoisomerase II
`Inhibitor, in Renal Cell Cancer with
`Assessment of Potential Surrogate Markers of
`Angiogenesis,” Clin. Cancer Res. 6:4697-4704
`(2000)
`
`Braybrooke
`
`2033
`
`“Proleukin®,” Physicians’ Desk Reference®,
`874-78 (47th ed. 1993)
`
`Proleukin®
`PDR
`
`2034
`
`Yagoda, A. et al., “Chemotherapy for
`Advanced Renal-Cell Carcinoma: 1983-1993,”
`Seminars Oncol. 22(1):42-60 (1995)
`
`Yagoda
`
`
`
`4
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2035
`
`2036
`
`Figlin, R.A. et al., “Multicenter, Randomized,
`Phase III Trial of CD8+ Tumor-Infiltrating
`Lymphocytes in Combination With
`Recombinant Interleukin-2 in Metastatic Renal
`Cell Carcinoma,” J. Clin. Oncol. 17(8):2521-
`29 (1999)
`
`Motzer, R.J. et al., “Phase III Trial of
`Interferon Alfa-2a With or Without 13-cis-
`Retinoic Acid for Patients With Advanced
`Renal Cell Carcinoma,” J. Clin. Oncol.
`18(16):2972-80 (2000)
`
`Figlin
`
`Motzer 2000
`
`2037
`
`Pagliaro, L. et al., “A Phase II Trial of
`Bryostatin-1 for Patients with Metastatic Renal
`Cell Carcinoma,” Cancer 89(3):615-18 (2000)
`
`Pagliaro
`
`Gollob, J. et al., “Phase I Trial of Twice-
`Weekly Intravenous Interleukin 12 in Patients
`with Metastatic Renal Cell Cancer or
`Malignant Melanoma: Ability to Maintain IFN-
`γ Induction Is Associated with Clinical
`Response,” Clin. Cancer Res. 6:1678-92
`(2000)
`
`Motzer, R.J. et al., “Phase I Trial of
`Subcutaneous Recombinant Human
`Interleukin-12 in Patients with Advanced Renal
`Cell Carcinoma,” Clin. Cancer Res. 4:1183-91
`(1998)
`
`Gollob
`
`Motzer 1998
`
`Kandel, E.S. & N. Hay, “The Regulation and
`Activities of the Multifunctional
`Serine/Threonine Kinase Akt/PKB,” Exper.
`Cell Res. 253:210-29 (1999)
`
`Kandel
`
`Downward, J. “Mechanisms and consequences
`of activation of protein kinase B/Akt,” Current
`Op. Cell Biol. 10(2):262-67 (1998)
`
`Downward
`
`2038
`
`2039
`
`2040
`
`2041
`
`
`
`5
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2042
`
`Sekulić, A. et al., “A Direct Linkage between
`the Phosphoinositide 3-Kinase-AKT Signaling
`Pathway and the Mammalian Target of
`Rapamycin in Mitogen-stimulated and
`Transformed Cells,” Cancer Res. 60:3504-13
`(2000)
`
`Sekulić
`
`2043
`
`Alexandre, J. et al., “Rapamycin and CCI-
`779,” Bull. Cancer 86(10):808-11 (1999)
`
`Alexandre
`1999
`
`2044
`
`2045
`
`2046
`
`2047
`
`2048
`
`Douros, J. & M. Suffness, “New Natural
`Products Under Development at the National
`Cancer Institute,” in 76 Recent Results in
`Cancer Research, 153-75 (S.K. Carter et al.,
`eds., 1981)
`
`Screening Data Summary, DEVELOPMENTAL
`THERAPEUTICS PROGRAM, DIVISION OF CANCER
`TREATMENT, NATIONAL CANCER INSTITUTE,
`1983 (available at
`https://wiki.nci.nih.gov/download/attachments/
`211714065/Instruction_14.pdf?version=1&mo
`dificationDate=1403007070000&api=v2,
`accessed 4/3/2018)
`
`Douros, J. & M. Suffness, “New antitumor
`substances of natural origin,” Cancer
`Treatment Revs. 8:63-87 (1981)
`
`Marsoni, S. & Wittes, R., “Clinical
`Development of Anticancer Agents – A
`National Cancer Institute Perspective,” Cancer
`Treatment Reports 68(1):77-85 (1984)
`
`Goldin, A. et al., “Current Results of the
`Screening Program at the Division of Cancer
`Treatment, National Cancer Institute,” Europ.
`J. Cancer 17:129-42 (1981)
`
`Douros I
`
`NCI
`
`Douros II
`
`Marsoni
`
`Goldin
`
`
`
`6
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`2054
`
`2055
`
`Houchens, D. et al., “Human Brain Tumor
`Xenografts in Nude Mice as a Chemotherapy
`Model,” Eur. J. Cancer Clin. Oncol.
`19(6):799-805 (1983)
`
`Stadler, W. et al., “Flavopiridol, a Novel
`Cyclin-Dependent Kinase Inhibitor, in
`Metastatic Renal Cancer: A University of
`Chicago Phase II Consortium Study,” J. Clin.
`Oncol. 18(2):371-75 (2000)
`
`Lümmen, G. et al., “Granulocyte-Macrophage
`Colony-Stimulating Factor and Interferon-
`Alpha 2B in Patients with Advanced Renal
`Cell Carcinoma,” Urol. Int. 61:215-19 (1998)
`
`Tabernero, J. et al., “Dose- and Schedule-
`Dependent Inhibition of the Mammalian Target
`of Rapamycin Pathway With Everolimus: A
`Phase I Tumor Pharmacodynamic Study in
`Patients With Advanced Solid Tumors,” J.
`Clin. Oncol. 26(10):1603-10 (2008)
`
`O’Donnell, A. et al., “A phase I study of the
`oral mTOR inhibitor RAD001 as monotherapy
`to identify the optimal biologically effective
`dose using toxicity, pharmacokinetic (PK) and
`pharmacodynamic (PD) endpoints in patients
`with solid tumours,” Proceedings Am. Soc’y
`Clin. Oncol., 22:200 (2003)
`
`Certican® U.K. Label, NOVARTIS PHARMS.,
`available at
`https://www.medicines.org.uk/emc/product/19
`20/smpc (last updated Oct. 2, 2017)
`
`Utiger, R.D. “Pituitary Tumors,” in Clinical
`Hematology and Oncology, 1139-43 (B. Furie
`et al. eds., 2003)
`
`Houchens
`
`Stadler 2000
`
`Lümmen
`
`Tabernero
`
`O’Donnell
`
`
`
`Furie
`
`
`
`7
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2056
`
`2057
`
`2058
`
`2059
`
`Creaven, P.J. & D. Raghavan, “Principles of
`Chemotherapy for Genitourinary Cancer:
`Implications for Development of New
`Anticancer Drugs,” Principles & Practice of
`Genitourinary Oncology 89-110 (1997)
`
`Creaven
`
`Muggia, F.M. & M.D. Green, “New
`anthracycline antitumor antibiotics,” Critical
`Revs. Oncology/Hematology 11:43-64 (1991)
`
`Muggia
`
`Hidalgo, M. et al., “CCI-779, a Rapamycin
`Analog and Multifaceted Inhibitor of Signal
`Transduction: a Phase I Study,” Proceedings
`Amer. Soc’y of Clin. Oncol. 187a (2000)
`
`Hidalgo
`ASCO 2000
`
`Jacobsen, W. et al., “Comparison of the In
`Vitro Metabolism of the Macrolide
`Immunosuppressants Sirolimus and RAD,”
`Transplantation Proceedings 33:514-15 (2001)
`
`Jacobsen
`
`2060
`
`Ritschel, W.A., Handbook of Basic
`Pharmocokinetics, 6-7, 264-267 (4th ed. 1992)
`
`Ritschel
`
`2061
`
`2062
`
`2063
`
`Rohde, D. et al., “Experimental and Clinical
`Efficacy of 2’,2’-Difluorodeoxycytidine
`(Gemcitabine) against Renal Cell Carcinoma,”
`Oncology 53:476-81 (1996)
`
`Rohde
`
`Sakurada, A. et al., “Infrequent Genetic
`Alterations of the PTEN/MMAC1 Gene in
`Japanese Patients with Primary Cancers of the
`Breast, Lung, Pancreas, Kidney, and Ovary,”
`Jpn. J. Cancer Res. 88:1025-28 (1997)
`
`Cairns, P. et al., “Point mutation and
`homozygous deletion of PTEN/MMAC1 in
`primary bladder cancers,” Oncogene 16:3215-
`18 (1998)
`
`Sakurada
`
`Cairns
`
`
`
`8
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`Kola, I. & J. Landis, “Can the pharmaceutical
`industry reduce attrition rates?” Nat. Revs.
`Drug Discovery 3(8):711-15 (2004)
`
`Kola
`
`A.J. Pantuck et al., “Therapeutic Strategies,
`Predicting Outcomes in Patients With Renal
`Cell and Transitional Cell Carcinomas,” Rev.
`Urol. 2(1):22-24 (2000)
`
`Clinical Trial No. NCT00019539,
`“Monoclonal Antibody Therapy in Treating
`Patients With Advanced Kidney Cancer,”
`available at
`https://clinicaltrials.gov/ct2/show/NCT000195
`39?term=NCT00019539 (last accessed Dec. 5,
`2016)
`
`Clinical Trial No. NCT00009919, “SU5416 in
`Treating Patients With Metastatic Kidney
`Cancer That Has Not Responded to Previous
`Treatment,” available at
`https://clinicaltrials.gov/ct2/show/NCT000099
`19 (last accessed Dec. 5, 2016)
`
`Pantuck, A.J. et al., “Cytoreductive
`Nephrectomy for Metastatic Renal Cell
`Carcinoma: Is It Still Imperative in the Era of
`Targeted Therapy,” Clin. Cancer Res. 13(2
`Suppl.):693s-696s (2007)
`
`Pantuck 2000
`
`NCT ’539
`
`NCT ’919
`
`Pantuck 2007
`
`Shefner, A.M. & M. Marlow, “Preliminary
`Drug Trials in a Renal Cell Carcinoma Animal
`Model,” Cancer Chemotherapy Reports
`5(1):145-49 (1975)
`
`Shefner
`
`Hojo, M. et al., “Cyclosporine induces cancer
`progression by a cell-autonomous mechanism,”
`Nature 397:530-34 (1999)
`
`Hojo
`
`
`
`9
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2071
`
`2072
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`Fosså, S.D. et al., “Vinblastine in Metastatic
`Renal Cell Carcinoma EORTC Phase II Trial
`30882,” Eur. J. Cancer 28A(415):878-80
`(1992)
`
`Morita, T. et al., “Antitumour effect of a
`synthetic analogue of fumagillin on murine
`renal carcinoma,” British J. Urology 74:416-21
`(1994)
`
`Stadler, W.M. et al., “Multi-Institutional Study
`of Angiogenesis Inhibitor TNP-470 in
`Metastatic Renal Carcinoma,” J. Clin. Oncol.
`17(8):2541-45 (1999)
`
`Brunda, M.J. et al., “Antitumor and
`Antimetastatic Activity of Interleukin 12
`against Murine Tumors,” J. Exp. Med.
`178:1223-30 (1993)
`
`Motzer, R.J. et al., “Randomized Multicenter
`Phase II Trial of Subcutaneous Recombinant
`Human Interleukin-12 Versus Interferon-α2a
`for Patients with Advanced Renal Cell
`Carcinoma,” J. Interferon Cytokine Res.
`21:257-63 (2001)
`
`Bertolini, F. et al., “Endostatin, an
`antiangiogenic drug, induces tumor
`stabilization after chemotherapy or anti-CD20
`therapy in a NOD/SCID mouse model of
`human high-grade non-Hodgkin lymphoma,”
`Blood 96(1):282-87 (2000)
`
`Fosså
`
`Morita
`
`Stadler 1999
`
`Brunda
`
`Motzer 2001
`
`Bertolini
`
`Lopes de Menezes, D.E. et al., “In Vitro and in
`Vivo Targeting of Immunoliposomal
`Doxorubicin to Human B-Cell Lymphoma,” J.
`Cancer Res. 58:3320-30 (1998)
`
`Lopes de
`Menezes
`
`
`
`10
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2078
`
`Altman, R. & Sarg, M.J., The Cancer
`Dictionary pages 28, 269, 285 (1992)
`
`Pazdur, R., et al. (eds.), Chapters 6-16, Cancer
`Management: A Multidisciplinary Approach:
`Medical, Surgical, & Radiation Oncology, 91-
`299 (4th ed. 2000)
`
`Altman
`
`Pazdur
`
`2079
`
`2080
`
`2081
`
`2082
`
`2083
`
`2084
`
`2085
`
`2086
`
`Expert Declaration of Krishna V. Komanduri,
`M.D.
`
`Komanduri
`
`Curriculum vitae of Krishna V. Komanduri,
`M.D.
`
`Komanduri
`CV
`
`Rowinsky, E.K. & R.C. Donehower, “The
`Clinical Pharmacology and Use of
`Antimicrotubule Agents in Cancer
`Chemotherapeutics,” Pharmac. Ther. 52:35-84
`(1991)
`
`Foster, B.J. et al., “A strategy for the
`development of two clinically active cisplatin
`analogs: CBDCA and CHIP,” Cancer
`Chemother. Pharmacol. 395-404 (1990)
`
`Rowinsky
`
`Foster
`
`Harvey, S.C. & C.D. Withrow, “Basic
`Pharmacokinetics,” in Remington’s Pharm. Sci.
`725-30 (A.R. Gennaro et al. eds., 18th ed.
`1990)
`
`Remington’s
`
`Sokoloff, M.H. et al., “Current Management of
`Renal Cell Carcinoma,” CA Cancer J. Clin.
`46(5):284-302 (1996).
`
`Sokoloff 1996
`
`ACHN (ATCC® CRL-1611™), AMERICAN
`TYPE CULTURE COLLECTION (ATCC), available
`at https://www.atcc.org/Products/All/CRL-
`1611.aspx#characteristics (accessed March 29,
`2018)
`
`ACHN
`
`
`
`11
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`A-498 (ATCC® HTB-44™), AMERICAN TYPE
`CULTURE COLLECTION (ATCC), available at
`https://www.atcc.org/Products/All/HTB-
`44.aspx#generalinformation (accessed March
`29, 2018)
`
`ATCC A-498
`
`A-498, HYPERCLDB, available at
`http://bioinformatics.hsanmartino.it/cldb/cl164.
`html (accessed March 29, 2018)
`
`HYPERCLDB
`A-498
`
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`Nobuhara
`
`De Mulder
`
`Skillings
`
`Burris
`
`Cho
`
`Nobuhara, M. et al., “The Inhibition of
`Neoplastic Cell Proliferation with Human
`Natural Tumor Necrosis Factor,” Jpn. J.
`Cancer Res. 78(2):193-201 (1987)
`
`De Mulder, P.H.M. et al., “Gemcitabine: a
`phase II study in patients with advanced renal
`cancer,” Cancer Chemother. Pharmacol.
`37:491-95 (1996)
`
`Skillings, J. et al., “A Phase II Study of
`Recombinant Tumor Necrosis Factor in Renal
`Cell Carcinoma: A Study of the National
`Cancer Institute of Canada Clinical Trials
`Group,” J. Immunotherapy, 11:67-70 (1992)
`
`2092
`
`Second Expert Declaration of Howard A.
`Burris, III M.D.
`
`2093
`
`Excerpts of September 14, 2017 Trial
`Testimony of Dr. Daniel Chang Cho, in
`Novartis Pharms. Corp. v. West-Ward Pharms.
`Int’l Ltd., No. 15-cv-474-RGA, 2017 U.S. Dist.
`LEXIS 205600 (D. Del. Dec. 14, 2017)
`
`
`
`12
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`Excerpts of March 3, 2017 Deposition
`Testimony of Dr. Daniel Chang Cho, in
`Novartis Pharms. Corp. v. West-Ward Pharms.
`Int’l Ltd., No. 15-cv-474-RGA, 2017 U.S. Dist.
`LEXIS 205600 (D. Del. Dec. 14, 2017)
`
`Robbins, S.L. et al., Chapter 15, “Diseases Of
`White Cells, Lymph Nodes, And Spleen,”
`Pathologic Basis Of Disease, 653-705 (3rd ed.
`1984)
`
`Buzaid, A.C. & E. Cadman, Chapter 52:
`“Pharmacology Of Antineoplastic Agents And
`Mechanisms Of Multidrug Resistance,”
`Hematology Basic Principles And Practice
`(Hoffman, R. et al. eds., 1991)
`
`Zisman, A., A.J. Pantuck, & A.S. Belldegrun,
`“Molecular-based Therapies for Renal Cell
`Carcinoma,” Curr. Urol. Reports 2:55-61
`(2001)
`
`Molldrem, J.J. et al., “Overexpressed
`Differentiation Antigens As Targets Of Graft-
`Versus-Leukemia Reactions,” Curr. Opin.
`Hematol. 9:503-08 (2002)
`
`Zisman, A., A.J. Pantuck, & A. Belldegrun,
`“Gene and Immune-based Therapies for
`Genitourinary Malignancies: Current Status
`and Future Prospects,” Israel Med. Assoc. J.
`2:33-42 (2000)
`
`Cho
`
`Robbins
`
`Buzaid
`
`Zisman 2001
`
`Molldrem
`
`Zisman 2000
`
`2100
`
`Motzer, R.J. & P. Russo, “Systemic Therapy
`For Renal Cell Carcinoma,” J. Urology
`163:408-417 (2000)
`
`Russo
`
`
`
`13
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`Pantuck, A.J., A. Zisman, & A. Belldegrun,
`“Gene and immune therapy for renal cell
`carcinoma,” Int’l J. Urology 8:S1-S4 (2001)
`
`Pantuck 2001
`
`2101
`
`2102
`
`2103
`
`2104
`
`Ritschel, W.A., Handbook of Basic
`Pharmacokinetics, 1-18, 225-69 (4th ed. 1992)
`(served but not filed on April 25, 2018)
`
`Altman, R. & Sarg, M.J., The Cancer
`Dictionary pages 28-29, 269, 285 (1992)
`(served but not filed on April 25, 2018)
`
`Harvey, S.C. & C.D. Withrow, “Basic
`Pharmacokinetics,” in Remington’s Pharm. Sci.
`725-45 (A.R. Gennaro et al. eds., 18th ed.
`1990)
`(served but not filed on April 25, 2018)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2105
`
`Copy of Email Exchange Between Laura
`Fishwick and Daniel Evans
`(served but not filed on April 25, 2018)
`
`2106
`
`Declaration of Charlotte Jacobsen Regarding
`Exhibits 2031, 2033, 2045, 2054, 2055, 2060,
`2066, 2067, 2078, 2079, 2084, 2086, 2087,
`2088, 2102, 2103, 2104, and 2105
`(served but not filed on April 25, 2018)
`
`2107
`
`Declaration of Howard A. Burris, III MD
`Regarding Exhibit 2055
`(served but not filed on April 25, 2018)
`
`2108
`
`Declaration of Daniel Chang Cho in West-
`Ward Pharms. Int’l Ltd. v. Novartis Pharms.
`Corp., IPR2018-00507, EX. 1112 (P.T.A.B.
`Jan. 17, 2018)
`(served but not filed on April 25, 2018)
`
`
`
`14
`
`
`
`Exhibit
`
`Description
`
`Abbreviation
`
`2109
`
`Curriculum vitae of Daniel Chang Cho in
`West-Ward Pharms. Int’l Ltd. v. Novartis
`Pharms. Corp., IPR2018-00507, EX. 1113
`(P.T.A.B. Jan. 17, 2018) (served but not filed
`on April 25, 2018)
`
`2110
`
`List of Exhibits Cited in the Expert Declaration
`of Dr. Krishna V. Komanduri (Ex. 2080)
`
`Declaration In Support Of Patent Owner
`Novartis’s Motion For Pro Hac Vice
`Admission Of Jared L. Stringham Under 37
`C.F.R. § 42.10
`
`
`
`
`
`
`
`2111
`
`2112
`
`Wasik, M.A. et al., “Constitutive Secretion of
`Soluble Interleukin-2 Receptor by Human T
`Cell Lymphoma Xenografted into SCID Mice,”
`Am. J. Pathology 144(5): 1089-97 (1994)
`
`Wasik 1994
`
`2113
`
`July 27, 2018 Deposition Testimony of Dr.
`Allan J. Pantuck
`
`2114
`
`Confidential Settlement Agreement Between
`Breckenridge Pharmaceutical, Inc. and
`Novartis Pharmaceuticals Corporation (filed
`for access by the “Board Only”)
`
`
`
`
`
`
`
`
`
`
`
`15
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing Patent Owner’s Exhibit List 9 was
`
`served on August 8, 2018 by causing it to be sent by email to counsel for Petitioner
`
`at the following email addresses:
`
`
`Keith A. Zullow (kzullow@goodwinprocter.com)
`
`Marta E. Delsignore (mdelsignore@goodwinprocter.com)
`
`
`
`Dated: August 8, 2018
`
`
`
`
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`
`
`16
`
`